EP1263453A4 - PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX - Google Patents

PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX

Info

Publication number
EP1263453A4
EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
Authority
EP
European Patent Office
Prior art keywords
polymermatrix
regulating
time
biologically active
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01939971A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1263453A2 (en
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1263453A2 publication Critical patent/EP1263453A2/en
Publication of EP1263453A4 publication Critical patent/EP1263453A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01939971A 1999-12-31 2001-01-02 PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX Ceased EP1263453A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US174137P 1999-12-31
PCT/US2001/000030 WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Publications (2)

Publication Number Publication Date
EP1263453A2 EP1263453A2 (en) 2002-12-11
EP1263453A4 true EP1263453A4 (en) 2008-02-20

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939971A Ceased EP1263453A4 (en) 1999-12-31 2001-01-02 PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX

Country Status (5)

Country Link
EP (1) EP1263453A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003519164A (cg-RX-API-DMAC7.html)
AU (1) AU784226B2 (cg-RX-API-DMAC7.html)
CA (1) CA2396037A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001049249A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251864A4 (en) * 1999-12-31 2006-02-22 Univ Rutgers PHARMACEUTICAL FORMULATION COMPRISING A POLYMERIC MIXTURE AND AN ACTIVE COMPOUND FOR TIME-RELEASED RELEASE
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
JP5794721B2 (ja) 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
US8636753B2 (en) 2006-02-08 2014-01-28 Tyrx, Inc. Temporarily stiffened mesh prostheses
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
EP2079387B1 (en) 2006-11-06 2017-04-12 Tyrx, Inc. Mesh pouches for implantable medical devices
MX2009010396A (es) 2007-03-29 2009-12-02 Tyrx Pharma Inc Cubiertas polimericas biodegradables para implantes de mama.
JP5581202B2 (ja) 2007-05-02 2014-08-27 タイレックス・インコーポレイテッド ジヒドロキシベンゾエートポリマーおよびその使用
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
CA2737769C (en) 2008-09-22 2014-02-04 Arthur Schwartz Linear polyesteramides from aminophenolic esters
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
EP2437724B1 (en) * 2009-06-01 2015-09-30 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
EP2459638B1 (en) * 2009-07-31 2017-09-27 Rutgers, The State University of New Jersey Monomers and phase-separated biocompatible polymer compositions prepared therefrom for medical uses
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
AU2011293344B2 (en) 2010-08-25 2015-07-30 Medtronic, Inc. Novel medical device coatings
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6397190B2 (ja) 2010-11-12 2018-09-26 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． 有効医薬品成分を含む固着装置
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015069305A1 (en) 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
US20170231916A1 (en) * 2014-08-04 2017-08-17 Janssen Sciences Ireland Uc Compacted solid dosage form
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
AU2373200A (en) * 1999-02-05 2000-08-25 Alien Technology Corporation Apparatuses and methods for forming assemblies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
AU2925501A (en) 2001-07-16
JP2003519164A (ja) 2003-06-17
EP1263453A2 (en) 2002-12-11
WO2001049249A2 (en) 2001-07-12
WO2001049249A3 (en) 2002-01-17
CA2396037A1 (en) 2001-07-12
AU784226B2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
EP1263453A4 (en) PHARMACEUTICAL FORMULATION FOR REGULATING THE RELEASE IN TIME OF BIOLOGICALLY ACTIVE COMPOUNDS BASED ON A POLYMERIC MATRIX
EP1251864A4 (en) PHARMACEUTICAL FORMULATION COMPRISING A POLYMERIC MIXTURE AND AN ACTIVE COMPOUND FOR TIME-RELEASED RELEASE
DE69811735D1 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
DE60013445D1 (de) Pharmazeutische dosierungsformen zur kontrollierter pulsierender abgabe
EE200100714A (et) Farmatseutiliste ravimvormide pihustamissüsteemidja -meetodid
ATE228823T1 (de) Pharmazeutische aerosolformulierung
AT400295B (de) Orale feste pharmazeutische dosierungsform mit programmierter wirkstofffreisetzung und verfahren zu ihrer herstellung
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DK1242055T3 (da) Hydrogelstyret doseringsform til lægemidler
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE516812T1 (de) Pharmazeutische formulierungen zur anhaltenden arzneimittelfreisetzung
ATE317688T1 (de) Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE60118859D1 (de) Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DE69815524D1 (de) Haftende mikrokapseln enthaltend biologisch aktive substanzen
DE60232147D1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoff-freisetzung enthaltend milchsäure-glycolsäure copolymer, und verfahren zu deren herstellung
IL156262A0 (en) Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
ATE544448T1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20020723

A4 Supplementary search report drawn up and despatched

Effective date: 20080121

17Q First examination report despatched

Effective date: 20080718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110207